United States · Business news · Policy & Regulation · 18 Sept 2026
US Health Care
The White House said all 50 states, the District of Columbia and Puerto Rico have joined the arrangement that gives Medicaid programmes access to the most-favoured-nation prices agreed with drug manufacturers. It says 26 drugmakers, representing 90% of the branded US market, have signed such agreements, which tie US prices to those paid in comparable developed countries. The administration projects savings of more than $600 billion overall and nearly $65 billion for Medicaid over the next decade, and says the companies have committed about $170 billion to US manufacturing and research.
Medicaid is a low-margin channel for branded drugmakers because of existing mandatory rebates, so the revenue effect of matching overseas prices there is smaller than the same step would be in Medicare or commercial insurance. The exposure is to pharmaceutical and biotech companies with large Medicaid volumes, and to the managed-care insurers and pharmacy benefit managers that run Medicaid drug plans. The savings figures are the administration's own projections and the release gives no company-level detail.
Reported by The White House — “President Trump Extends Most Favored Nation Drug Pricing to Every Medicaid Program in America” ↗ on 18 Sept 2026.
Official series on 18 Sept 2026 or the last day before it, and the latest observation.
Option Care gives infusion drugs at home and in clinics instead of hospitals, a channel insurers favour because it costs less. McKesson, which already distributes specialty drugs, gains a stake in the provider that…
The advance was narrow: the report notes only about 25% of S&P 500 companies were trading above their 50-day average, and smaller companies fell on the day. Index gains are coming from AI chipmakers and from power…
Epcoritamab, sold as EPKINLY in the US and Japan and TEPKINLY in the EU, is approved so far for lymphoma that has returned after earlier treatment. A first-line label would open a much larger group of patients, and…
These are the first US deals to launch in the fourth quarter, and both are small, clinical-stage companies with no product revenue: the money funds trials. TRex Bio's lead programme has topline data due in mid-2027 and…